Company profile: Sirna Therapeutics
1.1 - Company Overview
Company description
- Provider of biotechnology research and development focused on RNA interference (RNAi) for human disease therapy, creating RNAi-based therapies to ultimately treat patients.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Sirna Therapeutics
Foghorn Therapeutics
HQ: United States
Website
- Description: Provider of targeted therapies leveraging its Gene Traffic Control platform to modulate the chromatin regulatory system, including FHD-286, an enzymatic BRG1/BRM inhibitor for AML and MDS; a selective BRM inhibitor and degrader for cancers with BRG1 mutations; and an ARID1B degrader for cancers with ARID1A mutations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Foghorn Therapeutics company profile →
Oncotelic Therapeutics
HQ: United States
Website
- Description: Provider of immuno-oncology therapeutics, developing RNA therapeutics and small molecule drugs against cancer and infectious diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oncotelic Therapeutics company profile →
EnPlusOne Biosciences
HQ: United States
Website
- Description: Provider of an ezRNA platform enabling incorporation of standard and non-standard nucleobases and their modifications, supporting installation of standard and phosphorothioated backbones, and integrating 2' modifications essential for siRNA therapeutics and novel variants. Offers 3' modifications including linkers and chain terminators for emerging RNA therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full EnPlusOne Biosciences company profile →
Laronde
HQ: United States
Website
- Description: Provider of an eRNA-based therapeutic platform, offering Endless RNA to program protein expression for therapeutic use; proprietary Natural NanoParticle technology to deliver biomolecules into human cells, enabling diverse administration routes and re-dosing; and AI-driven drug development using proprietary algorithms for rapid RNA medicine design.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Laronde company profile →
4D Molecular Therapeutics
HQ: United States
Website
- Description: Provider of transformative gene therapeutic products enabled by a Therapeutic Vector Evolution Platform using directed evolution to create customized viral vectors for targeted delivery. Offers R100 for retinal diseases, A101 for aerosol lung delivery, and C102 for intravenous heart muscle delivery, plus a product design & development engine and in-house GMP manufacturing and IND-enabling technical operations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full 4D Molecular Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Sirna Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Sirna Therapeutics
2.2 - Growth funds investing in similar companies to Sirna Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Sirna Therapeutics
4.2 - Public trading comparable groups for Sirna Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →